問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Urology

Division of Nuclear Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

周博敏CHOW, PO-MING
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

Recruiting Trial

37Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

周博敏

List

44Cases

2025-02-03 - 2033-05-03

Phase II/III

Active
一項第 II/III 期、開放性、跨國、多中心、隨機分配試驗，在 [177Lu]Lu-PSMA 精準放射標靶療法期間或之後惡化的 PSMA 陽性轉移性去勢抗性前列腺癌成人參與者中，比較 AAA817 相較於標準照護的治療

  • Condition/Disease

    PSMA-positive metastatic castration-resistant prostate cancer

  • Test Drug

    AAA817

Participate Sites
4Sites

Recruiting4Sites

2024-01-26 - 2029-02-28

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-06-30 - 2032-05-01

Phase II

Not yet recruiting
A Phase 2, Open-label, Multi-cohort Study to Assess the Efficacy and Safety of ASP5541 in Participants with Advanced Prostate Cancer

  • Condition/Disease

    Advanced Prostate Cancer

  • Test Drug

    ASP5541

Participate Sites
6Sites

Recruiting6Sites

2024-10-01 - 2029-09-30

Phase III

A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)

  • Condition/Disease

    Metastatic Castrate Resistant Prostate Cancer (mCRPC)

  • Test Drug

    PF-06821497 (MEVROMETOSTAT)EnzalutamideDocetaxel

Participate Sites
6Sites

Recruiting6Sites

2017-02-01 - 2023-02-28

Phase III

A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy

  • Condition/Disease

    Renal Cell Carcinoma

  • Test Drug

    Atezolizumab

Participate Sites
6Sites

Terminated5Sites

莊正鏗
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2022-02-01 - 2026-03-30

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2018-07-31 - 2020-01-31

Phase III

A Double-blind, Randomized, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Imidafenacin in Patients with Overactive Bladder

  • Condition/Disease

    Overactive Bladder

  • Test Drug

    Uritos

Participate Sites
12Sites

Terminated11Sites

2022-08-01 - 2026-08-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-06-01 - 2022-05-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2020-07-22 - 2025-11-30

Phase III

An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

  • Condition/Disease

    Locally Advanced or Metastatic Urothelial Cancer

  • Test Drug

    Enfortumab vedotin

Participate Sites
7Sites

Recruiting7Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB